Ultragenyx Pharmaceutical股票討論區

$Travere Therapeutic(TVTX.US)$  Phase 3
$CG Oncology(CGON.US)$  Phase 3
$美國聯合醫療(UTHR.US)$  Phase 3
$美國聯合醫療(UTHR.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3
$Insmed(INSM.US)$  Phase 3
$GlycoMimetics(GLYC.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$烏龍製藥(URGN.US)$  Phase 3
$Lyra Therapeutics(LYRA.US)$  Phase 3
$Citius Pharmaceuticals(CTXR.US)$  Phase 3
$Jaguar Health(JAGX.US)$  Phas...

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US)$  Phase 3
$CG Oncology(CGON.US)$  Phase 3
$和黃醫藥(HCM.US)$  Phase 3
$Viracta Therapeutics(VIRX.US)$  Phase 3
$GlycoMimetics(GLYC.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3
$FibroGen(FGEN.US)$  Phase 3
$烏龍製藥(URGN.US)$  Phase 3
$Lyra Therapeutics(LYRA.US)$  Phase 3
$Citius Pharmaceuticals(CTXR.US)$  Phase 3
$Marinus Pharmaceuticals(MRNS.US)$  Phase 3
$BioCardia(BCDA.US)$  Phase 3...

Gainers:
In reaction to earnings/guidance:
• $Silvergate Capital(SI.US)$ +10.7% (Silvergate (ticker: SI) notched net income of $38.6 million in the June quarter, delivering earnings per share (EPS) of $1.13.)
• $AxoGen(AXGN.US)$ +3.3% (guides Q2 revs above consensus; also makes changes to its commercial organization),
• $諾華製藥(NVS.US)$ + 3% (The Swiss pharmaceutical company on Tuesday posted net profit of $1.69 billion, down from...

$Mereo BioPharma(MREO.US)$ 市場消息説 $阿斯利康(AZN.US)$ 要收購 MREO，MREO 開出了$5, 艾菲克和花期銀行為顧問。
還有其他競價者 $諾華製藥(NVS.US)$  $Ultragenyx Pharmaceutical(RARE.US)$，最終價格可能高於問價。
https://www.moomoo.com/hans/news/post/11717638/why-mereo-biopharma-shares-are-jumping-today?src=2&futusource=news_stock_stockpagenews&report_type=stock&report_id=16171543&skintype=3&main_broker=WwogIDEwMDgKXQ==&level=1&data_ticket=c4c2b16555be25c729369d40292a2b01&utm_medium=futu_niuniu_share&utm_content=web_share&utm_campaign=new...

Upgrades
• $阿卡迪亞(ACAD.US)$: Canaccord Genuity Upgrades to Buy from Hold - PT $31 (from $30)
• $美國豪斯特酒店(HST.US)$: Raymond James Upgrades to Outperform from Market Perform - PT $21
• $曼格納國際(MGA.US)$: Raymond James Upgrades to Market Perform from Underperform - PT $68
• $美光科技(MU.US)$: Bernstein Upgrades to Outperform from Market Perform - PT $94 (from $58)
• $Ultragenyx Pharmaceutical(RARE.US)$: Credit Sui...

**Trader Tip**
Much of what we attribute to chance is just stubborn persistence.
Knowing what to do is very different from doing what you have to do.
Growth is what keeps life interesting, and it comes from doing hard stuff.
$Fate Therapeutics(FATE.US)$  $Ultragenyx Pharmaceutical(RARE.US)$  $梅西百貨(M.US)$  $Palantir(PLTR.US)$  $遊戲驛站(GME.US)$  $Nano Dimension(NNDM.US)$  $Denali Therapeutics(DNLI.US)$  $Alarm.com(ALRM.US)$